心脏类器官的生物构建策略及应用进展  

Research progress of biological construction strategy and application of cardiac organoids

作　　者：卢国庆 孙正宇 康品方[1] 唐碧[1] Lu Guoqing;Sun Zhengyu;Kang Pinfang;Tang Bi(Cardiovascular medicine department,the first affiliated hospital of Bengbu Medical College,Bengbu,Anhui,233004,China)

机构地区：[1]蚌埠医学院第一附属医院心血管内科,安徽蚌埠233004

出　　处：《齐齐哈尔医学院学报》2023年第7期664-670,共7页Journal of Qiqihar Medical University

基　　金：安徽省自然科学基金面上项目(2208085MH192);蚌埠医学院“512人才培育计划”中青年骨干教师培养对象(by51201214);安徽省高校协同创新项目(GXXT-2020-019);安徽省高校优秀青年项(2022AH030141)。

摘　　要：类器官是一种在体外利用人诱导多能干细胞构建的三维生物组织工程,能够高度的模拟体内细胞的生物学特性和功能。在全球范围内,心血管疾病是导致死亡的主要原因,相关研究主要局限于传统的二维细胞和动物模型。人类心脏类器官是复杂的多细胞聚集物,包括心脏组织的转录、功能和形态特征,在疾病机制研究、药物实验、再生医学等领域的发挥重要作用。本文主要介绍心脏类器官模型的生成方法,类器官在心血管疾病中应用进展,及心脏类器官的前景和面对的挑战。Organoids are three-dimensional(3D)biological tissue engineering constructed in vitro using human induced pluripotent stem cells(hiPSCs),which can highly mimic the biological characteristics and functions of cells in vivo.Cardiovascular disease is the leading cause of death worldwide,and related research is mainly limited to traditional two-dimensional(2D)cell and animal models.Human cardiac organoids(hCOs)are complex multicellular aggregates that including the transcriptional,functional and morphological characteristics of heart tissue,and play an important role in disease mechanism research,drug experimentation,regenerative medicine and other fields.This review focuses on the generation methods of cardiac organoids,the application progress of cardiac organoids in cardiovascular diseases,and the prospects and challenges of cardiac organoids.

关 键 词：心脏类器官 组织工程 生物策略 疾病模型 

分 类 号：R318.1[医药卫生—生物医学工程]